Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Editas Medicine Inc (EDIT)
NASDAQ:EDIT
Holding EDIT?
Track your performance easily
See the Price Targets and Ratings of:
EDIT Analyst Ratings
Moderate Buy
9 Buy
6 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
EDIT Stock 12 Month Forecast
Average Price Target
$9.08
▲(270.61% Upside)
| Highest Price Target$15.00 | Average Price Target$9.08 | Lowest Price Target$4.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Morgan Stanley
Reiterated
11/08/24
Evercore ISI
Upgraded
11/06/24
Barclays
Reiterated
11/06/24
Truist Financial
Reiterated
11/05/24
Chardan Capital
Reiterated
11/05/24
Oppenheimer
Reiterated
11/05/24
Stifel Nicolaus
Reiterated
11/05/24
JonesTrading
Assigned
11/05/24
Raymond James
Downgraded
11/04/24
TD Cowen
Reiterated
11/04/24
Wells Fargo
$7
Buy
185.71%
Upside
Assigned
11/04/24
Wall Street Analysts Are Bullish on Top Healthcare Picks
Leerink Partners
$8
Hold
226.53%
Upside
Reiterated
11/04/24
Cautious Optimism for Editas Medicine Amid Strategic Milestones and Competitive Pressures
RBC Capital
$5
Hold
104.08%
Upside
Reiterated
11/04/24
Editas Medicine price target lowered to $5 from $8 at RBC CapitalEditas Medicine price target lowered to $5 from $8 at RBC Capital
Robert W. Baird
$10
Buy
308.16%
Upside
Reiterated
11/04/24
Buy Rating for Editas Medicine Driven by Strategic Focus on In Vivo CRISPR Gene Editing and Intellectual Property Catalysts
Bank of America Securities
$15
Buy
512.24%
Upside
Reiterated
10/22/24
Editas Medicine: Strategic Shift Towards In Vivo Technologies and Long-term Growth Potential
Best Analysts Covering Editas Medicine
Which Analyst Should I Follow If I Want to Buy EDIT and Sell After:
1 Month
xxx
Success Rate
12/38 ratings generated profit
Average Return
+0.66%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 31.58% of your transactions generating a profit, with an average return of +0.66% per trade.
3 Months
xxx
Success Rate
13/38 ratings generated profit
Average Return
-3.91%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 34.21% of your transactions generating a profit, with an average return of -3.91% per trade.
1 Year
Success Rate
5/13 ratings generated profit
Average Return
-2.88%
reiterated a buy rating 19 days ago
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -2.88% per trade.
2 Years
xxx
Success Rate
7/13 ratings generated profit
Average Return
+27.62%
reiterated a xxx
rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 53.85% of your transactions generating a profit, with an average return of +27.62% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
EDIT Analyst Recommendation Trends
Rating
Jun 24
Aug 24
Sep 24
Oct 24
Nov 24
Strong Buy
5
10
7
11
13
Buy
2
2
2
3
3
Hold
11
16
10
11
12
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
28
19
25
28
Each month's total comprises the sum of three months' worth of ratings.
EDIT Financial Forecast
EDIT Stock Forecast FAQ
What is EDIT’s average 12-month price target, according to analysts?
Based on analyst ratings, Editas Medicine Inc’s 12-month average price target is $9.08.
What is EDIT’s upside potential, based on the analysts’ average price target?
Editas Medicine Inc has 270.61% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is EDIT a Buy, Sell or Hold?
Editas Medicine Inc has a consensus rating of Moderate Buy which is based on 9 buy ratings, 6 hold ratings and 0 sell ratings.
What is Editas Medicine Inc’s price target?
The average price target for Editas Medicine Inc is $9.08. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $15.00 ,the lowest forecast is $4.00. The average price target represents 270.61% Increase from the current price of $2.45.
The highest analyst price target is $15.00 ,the lowest forecast is $4.00. The average price target represents 270.61% Increase from the current price of $2.45.
What do analysts say about Editas Medicine Inc?
Editas Medicine Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
How can I buy shares of EDIT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.